In addition to systemic chemotherapy, for advanced NSCLC patients with epidermal growth factor receptor (EGFR) mutation, the use of EGFR–tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, or afatinib, as frontline or second-line treatment, can result in around 60% reduction in the risk of disease progression [8,9]. Here, EGFR is linked to non-small cell lung carcinoma.